SecBot SecBot
SECBOTREPLAY Home › Report › PYXS

PYXS · Pyxis Oncology announced positive updated Phase 1 monotherapy data for…

Pyxis Oncology, Inc. · 8-K filed Sep 9, 2026 at 07:34 ET

At the news

BULLISHIMPACT 6/10

8-K filed Sep 9, 2026 at 07:34 ET

Pyxis Oncology announced positive updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The data show a 36% confirmed objective response rate, 94% disease control rate, median progression-free survival of 6.2 months, and a 12-month overall survival probability of 79%, substantially exceeding historical control benchmarks. Safety was manageable with dose capping, supporting advancement into a pivotal Phase 3 trial (Headliner) planned for mid-2027.

  • 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR) in 2L+ R/M HNSCC (N=33 efficacy evaluable)
  • Median progression-free survival (mPFS) of 6.2 months; 12-month overall survival probability of 79% (median OS not yet reached)
  • Clinical activity observed across HPV status and prior-treatment subgroups, including prior EGFRi-exposed patients
  • No new safety signals; dose capping reduced frequency and severity of adverse events, especially peripheral neuropathy

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access